

# Transcript of the Testimony of **Paul Laskar**

**Date:** March 25, 2016

**Case:** Innpharma Licensing, Inc., et al. v. Senju Pharmaceutical Co., LTD., et al.



Ace-Federal Reporters, Inc.  
Phone: 202-347-3700  
Fax: 202-737-3638  
Email: [info@acefederal.com](mailto:info@acefederal.com)  
Internet: [www.acefederal.com](http://www.acefederal.com)

SENJU EXHIBIT 2331

1           IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
 2           BEFORE THE PATENT TRIAL AND APPEAL BOARD  
 3           Case IPR2015-00902 (Patent 8,669,290 B2)  
 4           Case IPR2015-00903 (Patent 8,129,431 B2) 1

5  
 6   INNOPHARMA LICENSING, INC.,                    )  
 7   INNOPHARMA LICENSING LLC,                    )  
 8   INNOPHARMA INC., INNOPHARMA LLC,            )  
 9   MYLAN PHARMACEUTICALS INC.,                )  
 10   and MYLAN INC.,                                )  
 11                    Petitioner,                                )  
 12           v.    )  
 13   SENJU PHARMACEUTICAL CO., LTD.,            )  
 14   BAUSCH & LOMB, INC., and                    )  
 15   BAUSCH & LOMB PHARMA HOLDINGS            )  
 16   CORP.,    )  
 17                    Patent Owner.                                )

18   -----)

19           VIDEOTAPED DEPOSITION OF PAUL LASKAR, PH.D.  
 20           Friday, March 25, 2016, 8:19 a.m.  
 21           Charlotte, North Carolina  
 22   Court Reporter: Nancy J. Martin, California CSR, RMR

Page 2	<p>1 Deposition of PAUL LASKAR, PH.D., a witness  2 called on behalf of Patent Owner, before Nancy J.  3 Martin, Notary Public, in and for the state of  4 North Carolina, at Alston &amp; Bird, 101 South Tryon  5 Street, Suite 4000, Charlotte, North Carolina, on  6 Friday, March 25, 2016, commencing 8:19 a.m.  7  8 -oOo-  9 APPEARANCES  10  11 ON BEHALF OF THE PATENT OWNER:  12 FINNEGAN, HENDERSON, FARABOW, FARRABOW,  13 GARRETT &amp; DUNNER, LLP.  14 JUSTIN J. HASFORD, ESQUIRE  15 BRADLEY J. MOORE  16 901 New York Avenue NW  17 Washington, D.C. 20001  18 (202) 408-4000  19  20  21  22</p>	Page 4
Page 3	<p>1 APPEARANCES (CONTINUED):  2  3 ON BEHALF OF THE PETITIONER:  4  5 ALSTON &amp; BIRD LLP  6 JITENDRA "JITTY" MALIK, PH.D., ESQUIRE  7 H. JAMES ABE, ESQUIRE  8 4721 Emperor Boulevard  9 Suite 400  10 Durham, North Carolina 27703  11 (919) 862-2210  12  13  14 ALSO PRESENT:  15 BRUCE MOODY, LEGAL VIDEOGRAPHER  16  17  18  19  20  21  22</p>	Page 5

I N D E X		
WITNESS/EXAMINATION		
		Page
1	PAUL LASKAR, PH.D.	
4	By Mr. Hasford	11, 185
5	By Dr. Malik	165
E X H I B I T S		
8	No. Description	Page
9	Exhibit 2264 Patent Owner's Notice of	12
10	Cross-Examination of	
11	Dr. Paul A. Laskar, Ph.D.,	
12	IPR2015-00902 (Patent 8,699,290 B2)	
13	4 pages	
14	Exhibit 2265 Patent Owner's Notice of	12
15	Cross-Examination of	
16	Dr. Paul A. Laskar, Ph.D.,	
17	IPR2015-00903 (Patent 8,129,431 B2)	
18	4 pages	
19	Exhibit 2266 Deposition transcript of Clayton	119
20	Heathcock, Ph.D. taken	
21	February 19, 2016, 273 pages	
22		

E X H I B I T S		
2	No. Description	Page
3	Exhibit 2267 Reply Expert Report of	134
4	Stephen G. Davies, D. Phil,	
5	25 pages	
6		
7	Exhibit 2268 Deposition transcript of	141
8	Robert C. Cykiert, M.D., taken	
9	February 26, 2016, 173 pages	
10	Exhibit 2269 Assessing Antioxidant and	148
11	Prooxidant Activities of Phenolic	
12	Compounds, 8 pages	
13	Exhibit 2270 U.S. Patent 6,265,44 B1,	156
14	10 pages	
15		
16		
17		
18		
19		
20		
21		
22		

Page 6	<p>1 EXHIBITS</p> <p>2 PREVIOUSLY MARKED AND REFERENCED HEREIN</p> <p>3 No. Description Page</p> <p>4 Exhibit 1001 U.S. Patent 8,129,431 B2, 28</p> <p>5 8 pages</p> <p>6 Exhibit 1001 U.S. Patent 8,669,290 B2, 28</p> <p>7 10 pages</p> <p>8 Exhibit 1004 U.S. Patent 4,910,225, 10 pages 59</p> <p>9 Exhibit 1011 Patent Abridgment, Australian 41</p> <p>10 Patent Office, AU-B-22042/88,</p> <p>11 31 pages</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p>	Page 8	<p>1 EXHIBITS</p> <p>2 PREVIOUSLY MARKED AND REFERENCED HEREIN</p> <p>3 No. Description Page</p> <p>4 Exhibit 1093 U.S. Patent 5,474,760, 131</p> <p>5 12 pages</p> <p>6 Exhibit 1104 Reply Declaration of Paul A. 13</p> <p>7 Laskar, Ph.D., 20 pages</p> <p>8 Exhibit 1105 U.S. Patent 2003/0053956 A1, 101</p> <p>9 23 pages</p> <p>10</p> <p>11 Exhibit 1148 International Patent Application, 148</p> <p>12 WO02/058610 A1, 66 pages</p> <p>13 Exhibit 1153 U.S. Patent 5,512,270, 11 pages 174</p> <p>14 Exhibit 2025 U.S. Patent 5,856,345, 7 pages 89</p> <p>15 Exhibit 2082 Declaration of Robert O. 83</p> <p>16 Williams III, Ph.D., 132 pages</p> <p>17 Exhibit 2097 Dunbrow Reference 79</p> <p>18 Exhibit 2105 Declaration of Stephen G. Davies, 54</p> <p>19 D.Phil, 56 pages</p> <p>20 Exhibit 2114 Deposition transcript of Paul A. 17</p> <p>21 Laskar, November 4, 2015,</p> <p>22 327 pages</p>
Page 7	<p>1 EXHIBITS</p> <p>2 PREVIOUSLY MARKED AND REFERENCED HEREIN</p> <p>3 No. Description Page</p> <p>4 Exhibit 1012 U.S. Patent 6,274,609 B1, 63</p> <p>5 11 pages</p> <p>6</p> <p>7 Exhibit 1019 Comparing the Surface Chemical 51</p> <p>8 Properties and the Effect of</p> <p>9 Salts on the Cloud Point of a</p> <p>10 Conventional Nonionic Surfactant,</p> <p>11 Octoxynol 9 (Triton X-100),</p> <p>12 and of Its Oligomer, Tyloxapol</p> <p>13 (Triton WR-1339), 7 pages</p> <p>14 Exhibit 1052 Curriculum Vitae of Paul A. 14</p> <p>15 Laskar, Ph.D., 4 pages</p> <p>16 Exhibit 1079 Deposition transcript of 122</p> <p>17 Robert O. Williams III, Ph.D.,</p> <p>18 taken March 9, 2016, 39 pages</p> <p>19 Exhibit 1091 U.S. Patent 3,272,700, 47</p> <p>20 5 pages</p> <p>21 Exhibit 1092 U.S. Patent 6,165,445, 126</p> <p>22 22 pages</p>	Page 9	<p>1 CHARLOTTE, NORTH CAROLINA, FRIDAY, MARCH 25, 2016</p> <p>2 8:19 A.M.</p> <p>3 --oOo--</p> <p>4 PROCEEDINGS</p> <p>5 THE VIDEOGRAPHER: We're now on the record.</p> <p>6 Please note that the microphones are sensitive and may</p> <p>7 pick up whispering and private conversations. Please</p> <p>8 turn off all cell phones or place them away from the</p> <p>9 microphones as they can interfere with the deposition</p> <p>10 audio. Recording will continue until all parties</p> <p>11 agree to go off the record.</p> <p>12 This is the deposition of Dr. Paul A. Laskar</p> <p>13 in the matter of Innopharma Licensing, Inc., v. Senju</p> <p>14 Pharmaceuticals Company, Ltd. These are Case</p> <p>15 Nos. IPR2015-00902 and IPR2015-00903 before the Patent</p> <p>16 Trial and Appeal Board of the United States Patent and</p> <p>17 Trademark Office.</p> <p>18 This video deposition is being taken at</p> <p>19 Alston &amp; Bird, LLP., 101 South Tryon Street,</p> <p>20 Suite 4000, Charlotte, North Carolina. The time is</p> <p>21 approximately 8:19 a.m. Today is March 25, 2015</p> <p>22 (sic). The court reporter is Ms. Nancy Martin,</p>

Page 10

1 appearing on behalf of Ace Federal Reporters of  
 2 Washington, D.C. The videographer is Bruce Moody,  
 3 also appearing on behalf of Ace Federal Reporters of  
 4 Washington, D.C.  
 5 Counsel will please state their appearances  
 6 for the record, and then the court reporter will swear  
 7 in the witness.  
 8 MR. HASFORD: Justin Hasford of Finnegan on  
 9 behalf of patent owner, and with me is my colleague,  
 10 Bradley Moore, also of Finnegan.  
 11 DR. MALIK: Jitendra Malik of Alston & Bird.  
 12 With me is my colleague, James Abe, also of Alston &  
 13 Bird, representing petitioner.  
 14  
 15 PAUL LASKAR, PH.D.,  
 16 having been first duly sworn,  
 17 was examined and testified as follows:  
 18  
 19 THE WITNESS: I would just like to correct.  
 20 I believe you used 2015. I think we're 2016 this  
 21 year.  
 22

Page 11

1 CROSS-EXAMINATION  
 2 BY MR. HASFORD:  
 3 Q. Good morning, Dr. Laskar.  
 4 A. Good morning.  
 5 Q. Would you please state your name and address  
 6 for the record.  
 7 A. Sure. My name is Paul Laskar. I reside at  
 8 603 Montecito Boulevard, Napa, California.  
 9 Q. Doctor, I represent the patent owner, Senju,  
 10 in these IPR proceedings. Today I will ask you  
 11 questions, and all I ask is that you answer my  
 12 questions truthfully and accurately. If you need a  
 13 break, just let me know. But if a question is  
 14 pending, please first answer the question, and then we  
 15 can take a break. If for any reason you do not  
 16 understand the question that I ask, please let me  
 17 know. If you answer a question, I will assume that  
 18 you understood the question. Is that okay?  
 19 A. It is.  
 20 Q. Is there any reason why you cannot testify  
 21 truthfully and accurately today?  
 22 A. No, there's no reason.

Page 12

1 MR. HASFORD: For the record, I'm handing  
 2 Dr. Laskar and petitioner's counsel copies of  
 3 Exhibits 2264 and 2265, which are Patent Owner's  
 4 Notices of Cross-Examination of Dr. Paul A Laskar.  
 5 (Deposition Exhibits 2264 and 2265  
 6 were marked for identification.)  
 7 MR. HASFORD: Counsel, can we stipulate that  
 8 Dr. Laskar is here today pursuant to Exhibits 2264 and  
 9 2265?  
 10 DR. MALIK: Yes.  
 11 MR. HASFORD: Counsel, can we also stipulate  
 12 that the questions that I ask, unless otherwise  
 13 stated, apply equally to IPR2015-00902 and  
 14 IPR2015-00903?  
 15 DR. MALIK: Yes. -902 and -903.  
 16 MR. HASFORD: Let the record reflect that we  
 17 hereby invoke the rule on witnesses pursuant to  
 18 Federal Rule of Evidence 615 prohibiting the showing  
 19 of the transcript of this deposition or discussing any  
 20 of its contents with Dr. Jayne Lawrence or any other  
 21 witness for Lupin in connection with any  
 22 IPR proceeding involving Prolensa.

Page 13

1 DR. MALIK: And your designation is noted.  
 2 We will follow the terms of the protective order.  
 3 MR. HASFORD: Thank you.  
 4 For the record, I'm handing Dr. Laskar and  
 5 petitioner's counsel copies of Exhibit 1104 entitled  
 6 "Reply Declaration of Paul A. Laskar, Ph.D."  
 7 (Previously marked Exhibit 1104.)  
 8 BY MR. HASFORD:  
 9 Q. Is Exhibit 1104 your "REPLY DECLARATION"  
 10 concerning U.S. Patent No. 8,129,431 and U.S. Patent  
 11 No. 8,669,290?  
 12 A. It certainly appears to be.  
 13 Q. If I refer to U.S. Patent No. 8,129,431 as  
 14 the "'431 patent," will you understand what I mean?  
 15 A. I will.  
 16 Q. If I refer to U.S. Patent No. 8,669,290 as  
 17 "the '290 patent," will you understand what I mean?  
 18 A. I will.  
 19 Q. If I refer to Exhibit 1104 as your "reply  
 20 declaration," will you understand what I mean?  
 21 A. Yes, I will.  
 22 Q. You did not yourself actually write your

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.